IOVA insider trading
NasdaqGM HealthcareIOVANCE BIOTHERAPEUTICS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Company website: www.iovance.com
IOVA insider activity at a glance
FilingIQ has scored 262 insider transactions for IOVA since Apr 3, 2017. The most recent filing in our index is dated May 11, 2026.
Across the full history, 26 open-market purchases
and 1 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on IOVA insider trades is 56.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
13F funds holding IOVA
Frequently asked
- How many insider trades does FilingIQ track for IOVA?
- FilingIQ tracks 262 Form 4 insider transactions for IOVA (IOVANCE BIOTHERAPEUTICS, INC.), covering filings from Apr 3, 2017 onwards. 39 of those were filed in the last 90 days.
- Are IOVA insiders net buyers or net sellers?
- Across the full Form 4 history for IOVA, 26 transactions (10%) were open-market purchases and 1 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does IOVA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is IOVA in?
- IOVANCE BIOTHERAPEUTICS, INC. (IOVA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.37B.
Methodology & sources
Every IOVA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.